Johnson & Johnson (JNJ) Share-based Compensation Growth (3y) (2012 - 2026)
Analysis
Johnson & Johnson (JNJ) Share-based Compensation Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | -83.20% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | -2.48% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 20.81% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 18.94% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | -0.49% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 9.95% |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 7.25% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | -83.20% |
| Mar 29, 2026 | -33.54% |
| Dec 28, 2025 | -35.02% |
| Mar 30, 2025 | 49.23% |
| Sep 29, 2024 | 83.42% |
| Jun 30, 2024 | -35.37% |
| Mar 31, 2024 | -8.25% |
| Dec 31, 2023 | 7.10% |
| Oct 1, 2023 | -38.08% |
| Jul 2, 2023 | -44.21% |
| Apr 2, 2023 | 75.18% |
| Jan 1, 2023 | 138.62% |
| Apr 3, 2022 | -59.25% |
| Oct 3, 2021 | -59.51% |
| Jul 4, 2021 | 75.28% |
| Apr 4, 2021 | -68.46% |
| Jan 3, 2021 | 103.57% |
| Sep 27, 2020 | 62.72% |
| Jun 28, 2020 | 124.23% |
| Mar 29, 2020 | -38.19% |